The era of bioengineering: how will this affect the next generation of cancer immunotherapy? by Graciotti, M. et al.
Graciotti et al. J Transl Med  (2017) 15:142 
DOI 10.1186/s12967-017-1244-2
REVIEW
The era of bioengineering: how will 
this affect the next generation of cancer 
immunotherapy?
Michele Graciotti1, Cristiana Berti2, Harm‑Anton Klok2 and Lana Kandalaft1,3*
Abstract 
Background: Immunotherapy consists of activating the patient’s immune system to fight cancer and has the great 
potential of preventing future relapses thanks to immunological memory. A great variety of strategies have emerged 
to harness the immune system against tumors, from the administration of immunomodulatory agents that activate 
immune cells, to therapeutic vaccines or infusion of previously activated cancer‑specific T cells. However, despite 
great recent progress many difficulties still remain, which prevent the widespread use of immunotherapy. Some of 
these limitations include: systemic toxicity, weak immune cellular responses or persistence over time and most ulti‑
mately costly and time‑consuming procedures.
Main body: Synthetic and natural biomaterials hold great potential to address these hurdles providing biocompat‑
ible systems capable of targeted local delivery, co‑delivery, and controlled and/or sustained release. In this review we 
discuss some of the bioengineered solutions and approaches developed so far and how biomaterials can be further 
implemented to help and shape the future of cancer immunotherapy.
Conclusion: The bioengineering strategies here presented constitute a powerful toolkit to develop safe and success‑
ful novel cancer immunotherapies.
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and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Since its first application in 1890 by William Coley who 
treated cancer patients with a mixture of killed bacteria 
observing complete remission in 10% of cases [1], can-
cer immunotherapy has “travelled” a long way, culminat-
ing in 2010 with the first personalized immunotherapy 
approved by FDA against prostate cancer [2]. However, 
despite its surprising progress, many hurdles still per-
sist that hamper success rates and wide applicability [3]. 
An anticancer immune response usually consists of an 
intricate network of events involving both innate and 
adaptive immune system first triggered by the uptake, 
processing and presentation of tumor antigens by antigen 
presenting cells (APCs), followed by T cell priming and 
activation and concluding with the infiltration of effector 
T cells to the tumor site where they exert their cytotoxic 
activity potentially leading to tumor clearance (Fig.  1). 
Although this is a spontaneous and natural occurring 
process, tumors usually develop various mechanisms 
in order to escape this immune response (e.g. antigen 
loss, release of immunoinhibitory signals in the tumor 
microenvironment and others), usually referred to as 
immunoediting [4]. Several therapeutic approaches act-
ing at different stages of the cancer immunity cascade 
have been developed over the years to overcome tumor 
immune escape. These can be classified in two: immuno-
therapies where cytokines or other immunomodulatory 
molecules are submitted to patients eliciting a cellular 
immune response in  vivo, or immunotherapies where 
immune cells are generated, stimulated and expanded 
ex vivo and then injected into patients. In this review we 
will describe the current challenges that these approaches 
present and how biomaterials and bioengineering could 
help solving central issues to advance and improve cancer 
immunotherapy.
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Immunomodulatory drug delivery
Chemotherapy is one of the most common therapies cur-
rently used for cancer treatment, however its application 
is often limited by large side effects linked to cytotoxic 
activity also on healthy tissues and cells, especially in 
patients already compromised by the disease. Although 
the use of cytotoxic drugs was traditionally thought to be 
immunosuppressive, this view is currently being changed 
by raising evidence [5]. One major factor to contribute in 
this sense is the so-called immunogenic cell death (ICD) 
which consists of the release of immunostimulatory mol-
ecules by cancer cells upon apoptotic cell death, lead-
ing to increased antigen uptake by dendritic cells (DCs) 
and immunization [6]. In recent years, to overcome 
side effects related to systemic administration, cancer 
drugs have been encapsulated in nanoparticles such as 
liposomes or poly(lactic-co-glycolic acid) (PLGA) nano-
particles (Fig.  2) and several are now FDA approved or 
being tested in clinical trials [7]. Nanoparticle encapsula-
tion ensures tumor delivery thanks to both high vascular 
permeability and poor lymphatic drainage of the diseased 
tissue, leading to passive accumulation of nanoparticles 
at the tumor site (so-called EPR effect: enhanced perme-
ability and retention effect) [8]. While the EPR effect has 
been shown to be effective in rodent models, translat-
ing this concept to the treatment of human cancers has 
proven more difficult [9]. Moreover, nanoparticles also 
provide increased drug stability due to shielding from the 
external environment, sustained release over time and 
increased local concentration. Interestingly, the impact 
of these approaches in the immunotherapy field is only 
starting to emerge very recently. A study by Zhao et  al. 
showed for example that delivery of oxaliplatin by PLGA 
nanocarriers [10] (NP-OXA) induced a stronger immune 
response both in  vitro (in co-culture assays of stimu-
lated DCs and T-cells) and in immunocompetent mice, 
compared to oxaliplatin alone (OXA). In particular, NP-
OXA-treated mice showed a higher proportion of tumor 
infiltrated lymphocytes (TILs), higher IFN-γ expression 
and increased tumor shrinkage compared to OXA treat-
ment alone [10]. These results show that encapsulation 
improved the drug immunogenicity by increasing ICD, 
thus leading to a more pronounced immune response. 
On the contrary, no significant differences were recorded 
between mice treated with gemcitabine alone or encap-
sulated, confirming that not all chemotherapeutic drugs 
and formulations are able to induce ICD or possess 
immunostimulatory effects [11]. To that point, it will 
be important in the future to extend the test of chemo-
therapeutic nanomedicines also in immunocompetent 
mice instead of just the standard immunodeficient mice 
model [12] in order to investigate a possible role of the 
immune system in the response and fully reveal thera-
peutic potentials.
A similar strategy of nanoparticle encapsulation is also 
currently being pursued for the delivery of cytokines to 
boost and sustain the immune response against cancer 
cells in a more direct manner. Cytokines play a crucial 
role in stimulating and regulating the immune response 
against antigens, but their use in the clinic has been 
Fig. 1 The cancer immunity cycle. Diagram illustrating the seven major steps involved in the generation of an immune response against cancer 
with main bioengineering approaches developed so far (in red). aAPCs artificial antigen presenting cells, APCs antigen presenting cells, NPs nanopar‑
ticles. Adapted from [171]
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Nanoparcle Characteriscs
Liposomes
Spontaneously-assembled bilayered membranes 
containing an aqueous core. They can entrap both 
hydrophobic and hydrophilic drugs, providing a 
biocompable and non-toxic drug delivery system.
Synthec polymers 
(e.g. PLGA, g-PGA) biocompable and FDA-approved; 
usually immunogenic, slow and sustained cargo 
release.
Natural polymers
(e.g. albumin, HLA) biocompable, biodegradable, non-
toxic, usually low immunogenic. Monomers can vary in 
size which does not allow a strict control of the 
features. Can be easily produced by cross-linking.
Micelles
nanosized aggregated formed by self-assembly of 
amphiphilic, surfactant molecules in aqueous soluon, 
able to encapsulate water-unsoluble drugs.
Dendrimers
highly branched, symmetrical molecular that are 
structurally perfect and monodisperse and which are 
obtained by step-wise synthec protocols via 
convergent or divergent strategies.
Gold nanoparcle
Easily produced and highly stable; inert material; used 
in thermal therapy, in vivo imaging, and in radio-
sensizaon also in the clinic.
Carbon 
nanoparcle
Offers mechanical sffness and chemical stability; 
selecvely enter the lymphac vessels rather than 
blood capillaries due to the molecular size and 
permeability; parcularly suitable for biomaging and 
diagnosc applicaons as well as thermal therapy.
Quantum dots
Nanometer-sized crystals composed of 
semiconductors; mainly used for diagnosc and 
fluorescence imaging thanks to the ability of 
mulplexing (disnct excitaon and emission 
wavelengths).
Silica nanoparcle
Non-toxic and biocompable systems; easy to produce 
and funconalize; are highly stable in a variety of 
environments.
Ion oxide 
nanoparcle
Composed of magnete or maghemite cores stabilized 
with a hydrophilic surface coang; their magnec 
properes allow controlled delivery through external 
magnec fields.
Fig. 2 Nanoparticle classification and main characteristics. γ-PGA poly(γ‑glutamic acid), HA hyaluronic acid, PLGA poly(lactic‑co‑glycolic acid)
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greatly limited due to harmful side effects linked with 
their pleiotropic nature and often dual role in simultane-
ously stimulating and suppressing the immune response 
at different levels [13]. As for chemotherapeutic drugs, 
nanoparticle encapsulation offers a potential solution 
also in this context by providing target delivery at the 
tumor site, therefore avoiding systemic toxicity. Recently, 
several groups have tested the delivery of IL-12 loaded 
on chitosan nanoparticles either as a recombinant pro-
tein [14, 15] or as encoding DNA for gene therapy [16], 
obtaining promising results. IL-12 is a powerful, proin-
flammatory cytokine that enhances  TH1 cell differentia-
tion, proliferation of activated T cells and natural killer 
(NK) cells and cell-mediated immunity [17]. Zaharoff 
et  al. reported that IL-12/chitosan nanoparticles were 
superior to IL-12 alone in terms of overall survival and 
cytokine production in a mouse model of bladder cancer, 
further inducing 100% protection to tumor rechallenge 
in previously cured mice, lasting lymphocytic infiltra-
tion and a tumor-specific adaptive immune response [14, 
15]. Significant results in terms of cytokine production 
and positive therapeutic outcome in mice have also been 
recorded with nanoparticle-mediated IL-12 gene therapy 
[16]. In addition, nanoparticle encapsulation has been 
reported for IL-2 [18–20], IL-15 [21], IL-10 siRNA [22], 
GM-CSF [23, 24], and the toll-like receptor (TLR) ago-
nists CpG oligodeoxynucleotides (CpG-ODN) [25–27] 
and Poly I:C [28, 29], with positive outcomes in mouse 
models (Table 1). All these studies collectively confirmed 
the previous assumption that nanoparticle formulations 
are safer and induce better therapeutic effects than their 
free-soluble counterparts due to controlled local admin-
istration and higher concentration at the tumor site in 
virtue of the EPR effect. This innovative approach opens 
therefore a new scenario where immunomodulatory 
agents previously discontinued due to toxicity could be 
potentially reconsidered, improved by encapsulation and 
tested for future cancer immunotherapy. On the other 
hand, also treatments discarded due to low efficacy could 
be revisited and implemented in new biomaterials for-
mulations [30]. Interestingly, a novel approach combining 
delivery of both cytotoxic drugs and cytokines through 
nanoparticles is also being pursued. The rationale here 
is of a “two-hit” strike to cancer cells: a “first-hit” due to 
the drug cytotoxic effect leading to cell apoptosis, activa-
tion of APCs and subsequent triggering of an immune 
response, and a “second-hit” which improves and sus-
tains such immune response through the cytokine/TLR 
agonist action [10]. An example of this approach is the 
administration of lipid-coated cisplatin nanoparticles 
(LPC) followed by CpG-encapsulated liposomes 1  day 
after in a melanoma mouse model. Results showed that 
the combination treatment was far superior than both 
single mono-therapies in terms of controlling tumor 
growth, IFN-γ production, favourable cytokine profile 
and immunological memory [31]. Another study used a 
sequential administration of hyaluronic acid-paclitaxel 
complex followed by two types of PLGA nanoparticles 
loaded respectively with CpG-ODN and IL-10 siRNA 
also showing effective and synergistic results [32]. Other 
studies in a mouse model successfully used instead simul-
taneous co-delivery of chemotherapeutic drugs and 
immunomodulatory agents loaded in the same nanopar-
ticle (Table 1) [33, 34].
Concerning clinical work, several nanoparticles encap-
sulating chemotherapeutic drugs have been approved 
by FDA or are currently being tested in clinical trials for 
various types of malignancies; these include: liposomal 
doxorubicin [35–38], daunorubicin [39–43], irinotecan 
[44], vincristine [45–48] and albumin-bound paclitaxel 
(nab-paclitaxel) [49–52]. Despite this, clinical studies 
in combination with immunotherapy regimens are only 
slowly starting to emerge. One recent Phase I study inves-
tigated the combination of nab-paclitaxel with immuno-
therapy (co-administration of soluble IL-2 and IFN-α) in 
metastatic melanoma, but the study failed to identify the 
maximum tolerated dose due to recorded toxicity at the 
lowest concentration tested and also the limited num-
ber of patients enrolled (10) [53]. On the other hand, a 
Phase Ib study in metastatic triple-negative breast cancer 
patients confirmed the safety and the therapeutic benefit 
of a combination of a checkpoint inhibitor (anti-PD-L1: 
atezolizumab) with nab-paclitaxel, setting the basis for an 
ongoing Phase III clinical trial [54]. Finally, another Phase 
I study in recurrent ovarian cancer provided evidence for 
safety and biological activity of pegylated liposomal dox-
orubicin in combination with interleukin-18 [55]; similar 
positive outcomes were also reported for a combination 
of liposomal doxorubicin, anti-IL6-receptor antibody and 
IFN-α [56].
In light of these studies, it is clear that further work 
will be needed in the future to establish what the best 
encapsulation and administration strategies are (e.g. co-
encapsulation and co-delivery versus sequential adminis-
tration) as well as to identify the best drug combinations. 
To help the clinical translation the different formulations 
should also be tested in more sophisticated systems such 
as immunocompetent and/or humanized mouse models 
[57]. Finally, nanotherapies previously tested in humans 
(i.e. nab-paclitaxel) should be further investigated in 
combination with immunostimulatory agents (e.g. inter-
leukins, checkpoint inhibitors, etc.) with and/or without 
encapsulation to potentially improve therapeutic out-
comes [58].
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Adoptive T cell therapy
Adoptive T cell therapy (ACT) consists of the isolation 
of autologous tumor specific T cells from the patient’s 
peripheral blood or tumor biopsies, followed by ex vivo 
expansion and patient re-infusion to elicit an anti-cancer 
immune response [59]. Alternatively (especially for those 
type of cancers where cancer-specific T cells are less 
spontaneously occurring), T cells can be expanded from 
patient-genetically modified T cells expressing a tumor-
specific T Cell Receptor (TCR) or a chimeric TCR com-
posed of a synthetic antigen-binding Ig domain fused 
with TCR signalling components, called CAR receptor 
[60]. Despite promising results yielded in clinical trials 
for melanoma [61–63] and other cancer types [64–66], 
Table 1 List of recent studies investigating nanoparticle-mediated delivery of immunomodulatory agents
DOX doxorubicin, HA hyaluronic acid, LPS bacterial lipopolysaccharide, PEG polyethylene glycol, PEI polyethylenimine, PLGA poly(lactic-co-glycolic acid), PPS 
poly(propylene sulphide), PS polysaccharide, TIL tumor infiltrating lymphocytes
a Compared to free soluble agent, when applicable
Carrier Agent Model system Outcomea References
mPEG‑PLGA Oxaliplatin Pan02 pancreatic cancer mouse model Increased TIL levels, increased IFN‑γ 
production
[10]
Chitosan IL‑12 MB49 bladder tumor mouse model Induced antitumoral activity and  TH1 
cytokine expression
[14]
Chitosan IL‑12 MB49 and MBT‑2 bladder tumor mouse 
models
100% protection to tumor rechallenge in 
previously cured mice
[15]
Liposome Cisplatin CpG B16–F10 melanoma mouse model Tumor clearance, long‑term protection, 
 Treg downregulation
[31]
Nanodiamond CpG B16–F0 melanoma and 4T1 breast cancer 
mouse models
IL‑12 production and tumor shrinkage [25]
PEI IL‑2 plasmid B16–F1 melanoma mouse model Reduced tumor growth, prolonged sur‑
vival, increased TIL tumor infiltration
[18]
Chitosan IL‑2 plasmid BALB/c mouse inoculated with WEHI‑164 
in vitro transfected cells
Tumor mass volume decrease [162]
Hydroxyethyl starch IL‑2 C57BL/6 mouse model;  Rag2−/−γc−/− mice 
reconstituted with human  CD4+ T cells
In vivo T cell specific uptake [20]
Nanolipogel IL‑2 and TGF‑β inhibitor B16‑F10 melanoma mouse model Increased survival
Increased  CD8+ T cells tumor infiltration
[19]
Polylactic acid IL‑12, IL‑18, TNF‑α alone 
or in combinations
4T1 breast cancer mouse models IL‑12 and TNF‑α combination was the 
best condition for controlling tumor 
growth
[163]
PLGA‑PEI CpG, IL‑10 siRNA A20 B‑cell lymphoma mouse model Improved  TH1/TH2 cytokine expression 
ratio, Increased survival
[22]
HA
PLGA
PLGA
Paclitaxel
CpG
IL‑10 siRNA
B16–F10 melanoma mouse model Tumor growth inhibition
High  TH1/TH2 cytokine expression ratio
[32]
PPS CpG E.G7‑OVA and B16F10 mouse model Enhanced  TH1 cytokine secretion and 
protection to tumor rechallenge
[26]
silica GM‑CSF In vitro Increased macrophage proliferation [24]
Zinc oxide Poly I:C B16–F10 mouse melanoma model suppressed tumor cell growth [28]
PS Poly I:C C57BL/6 mouse model High IL6 production; tnfa, il15, il18, mip3a, 
and ip10 mRNA upregulation
[164]
PLGA Paclitaxel LPS B16–F10 mouse melanoma model Increased TIL levels and tumor regression [33]
Pyridyl disulfide Paclitaxel or CpG B16–F10 mouse melanoma model Slowed tumor growth, increased  CD8+/
CD4+ T cell ratio
[27]
Albumin Paclitaxel Phase I studies Combination with IL‑2, IFN‑α, cisplatin 
and temozolomide was too toxic; 
combination with atezolizumab was 
well tolerated
[53, 54]
Liposome DOX Phase I study Combination with IL‑18 is safe and bio‑
logically active
[55]
PEG‑liposome DOX Phase I study Functional IL‑6R blocking with tocili‑
zumab is feasible and safe in combina‑
tion with PEG‑liposomal DOX
[56]
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ACT still suffers from important drawbacks and chal-
lenges that limit its widespread use. Some of the major 
limitations include: (1) the time-consuming and costly 
procedure of ex  vivo cell expansion which requires 
5–6 weeks and specific equipment (e.g. bioreactors), (2) 
T cell persistence and functionality after infusion which 
usually necessitate administration of survival factors, and 
(3) systemic toxicity. Bioengineering approaches have 
recently tried to solve those issues by employing bioma-
terials in different ways. One successful strategy devel-
oped by Irvine and colleagues (so far in mouse models) is 
to conjugate nanoparticles loaded either with stimulating 
factors (IL-15 and IL-21) [67] or an immunosuppression-
blocking drug (NSC-87877) [68] directly on the surface 
of expanded T cells, prior to infusion. Interestingly, this 
strategy enabled the local delivery of immunomodula-
tory agents at high concentration that sustained T cell 
proliferation and effector function with greatly increased 
therapeutic advantages and minimized toxic effects com-
pared to systemic infusion [67, 68]. In a follow-up study, 
nanoparticles were decorated with T cell targeting anti-
bodies and used to stimulate ACT cells in  vivo instead 
of ex  vivo prior to infusion [69]. This approach has the 
advantage of enabling multiple rounds of stimulation 
by repeated nanoparticle injections rather than a single 
stimulation step ex  vivo. In particular, T cell targeting 
was achieved using either an ACT-T cell specific surface 
antigen (Thy1.1) to restrict targeting only to ACT cells, or 
IL-2 which would target less specifically the whole T cell 
compartment but with the advantage of providing also a 
stimulating signal. Results showed successful targeting 
efficiency of ACT cells with low binding to endogenous 
T cells in both cases; however IL-2-loaded nanoparticles 
were also able to induce repeated waves of ACT T cell 
expansion in tumor-bearing mice upon multiple injec-
tions, thanks to IL-2 signalling. Based on this proof-of-
concept, current work is focusing now on loading drugs 
and immunomodulatory molecules on these T-cell tar-
geting nanoparticles to further improve ACT therapeutic 
efficacy [69].
Concerning CAR T cells, a very recent breakthrough 
study explored the possibility to programme T cell in situ 
with the injection of DNA-carrying nanoparticles [70]. 
In particular, these nanoparticles were coated with anti-
CD3 antibodies to target the T cell compartment and 
loaded with DNA encoding for a leukaemia-specific 
CAR T cell receptor. Tests in an immunocompetent leu-
kaemia murine model showed correct T cell transduc-
tion and proliferation, leading to disease regression with 
an efficacy comparable to conventional adoptive CAR 
T cell therapy as well as reporting general safety with-
out any systemic toxicity [70]. Such an approach is very 
promising since it circumvents the need to isolate and 
manipulate T cells ex  vivo, an aspect linked with the 
major hurdles of current ACTs (see above) and it should 
be therefore further investigated in the future for other 
cancer types as well as considered for clinic translation. 
Another explored route to improve current ACTs is the 
employment of artificial antigen presenting cells (aAPCs) 
to stimulate T cell expansion. To provide appropriate sig-
nalling, aAPCs must present on their surface a peptide-
MHC complex that binds to the TCR (signal 1) and a 
CD28 antibody to provide co-stimulatory signalling (sig-
nal 2); in addition they could also provide adjuvants such 
as IL-2, IL-15 or IL-21 to further sustain T cell expan-
sion (signal 3) [71]. aAPCs offer the advantage of avoid-
ing the need to generate patient-specific DCs to stimulate 
tumor-specific T cells either ex vivo or in vivo as well as 
providing a versatile and cost-effective platform for T cell 
stimulation and expansion. On the other hand, a major 
disadvantage is the surface rigidity that fails to recapitu-
late the dynamic changes of the APC surface upon T-cell 
interaction. Important breakthroughs have been made 
recently in this field, thanks to the employment of bio-
materials, substantially contributing to improve aAPC 
efficacy. Initial studies demonstrated that polymer-based 
nanoparticles were much less efficient than microparti-
cles in inducing in vitro T cell functional responses (with 
notably no proliferation) suggesting that micron-sized 
beads, which are close in size to T cells, provide optimal 
T-cell stimulation [72]. However, Perica et  al. recently 
reported a nano-sized aAPC platform based on either 
iron-dextran paramagnetic nanoparticles or quantum dot 
nanocrystals both able to induce antigen specific-T cell 
proliferation and tumor shrinkage in a melanoma mouse 
model [73]. This discovery constitutes a critical improve-
ment for aAPCs in  vivo applications since, contrary to 
micro-sized particles, nano-sized ones are able to pas-
sively drain to lymph nodes [74] where they could gain 
access to a large pool of T cells to prime, making them 
more suitable and efficient for in vivo administration. The 
same group has also recently developed aAPC magnetic 
nanoparticles conjugated to CD28-antibody and MHC-I-
tumor antigen complexes as a strategy to isolate tumor-
specific T cells from peripheral blood using magnetic 
columns, followed by ex vivo expansion [75]. The enrich-
ment step was used to remove unspecific T cells that 
would compete with tumor-specific T cells for growth 
factors and decisively improved the antigen-specific cell 
fold expansion both in  vitro and in  vivo after transfer. 
Other important improvements came from using ellip-
soidal micro-particles instead of spherical ones in order 
to decrease the surface curvature and therefore increase 
the area available for T-cell contact [76] highlighting the 
importance of not only the stimulating signals, but also 
the geometry and design of aAPCs to provide a successful 
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stimulation. In light of this, it will be important in the 
future to also explore alternative geometries to mimic for 
example membrane protrusions or lamellipodia that are 
involved in T cell-APC interactions [77], in an attempt 
that will stimulate both the cancer immunotherapy and 
the bioengineering fields providing future synthetic chal-
lenges [78]. Finally, while up to now aAPCs have been 
prepared by randomly distributing ligands on their sur-
face, recent studies suggest that the juxtaposition and the 
relative positions of signal 1 and 2, as well as their surface 
density [79, 80], are also important to efficiently stimu-
late T cells [78]. For example, using planar arrays it was 
shown that the presence of anti-CD28 at the periphery of 
the T cell contact site increased IL-2 secretion by CD4 T 
cells compared with having these signals combined in the 
center of the synapse [81]. The need to precisely control 
the pattern and distribution of ligands constitutes there-
fore another challenge for future bioengineering syn-
thetic approaches.
Cancer vaccines
Therapeutic cancer vaccines consist of using cancer 
antigens to pulse dendritic cells either in vivo or ex vivo 
followed by administration to patients to induce a can-
cer-specific immune response. These vaccines are thera-
peutic rather than preventive, since they are designed 
to treat a disease, which is already in course. The first 
attempts in this sense were injections of autologous 
tumor cells or tumor specific proteins administered 
alone or with an adjuvant [82–84], while more recently 
an alternative strategy has been developed by stimulat-
ing directly dendritic cells ex  vivo with tumor associ-
ated or specific antigens (TAAs, TSAs) or whole tumor 
lysate (WTL) which are then re-infused into patients; this 
with the advantage of manipulating DCs during pulsing 
and activation to further improve their immunogenicity 
[85]. To this aim, dendritic cells can be obtained ex vivo 
by isolating monocyte precursors from peripheral blood 
followed by incubation with specific growth factors and 
cytokines such as GM-CSF, IL-4, IL-3, Flt3 ligand and 
c-Kit [86]. A great limitation of using TAAs is that the 
antigen(s) used has to be first identified and character-
ized which is not always possible for all types of cancers 
and it often requires extensive procedures. Moreover, 
there is also the possibility of immune escape by anti-
gen loss from cancer cells [87]. Alternatively, DCs have 
also been pulsed with autologous WTL obtained from 
patient’s cancer cells by irradiation or cycles of freezing 
and thawing with the advantage of using a much larger 
pool of potential antigens and also avoiding the need 
for antigen identification [88–91]. Our group recently 
reported that HOCl oxidation of WTL prior to DCs 
ex vivo pulsing and maturation increased the uptake and 
presentation as well as improving the therapeutic out-
come in an ovarian Phase I clinical trial [92, 93]. Another 
approach to increase immunogenicity of the lysate is to 
use heat, allowing increased production of heat shock 
proteins that further activate the immune response. 
This approach was tested in a pancreatic cancer mouse 
model with promising results [94]. Nonetheless, gen-
erating and activating DCs ex  vivo is a time-consuming 
and costly procedure that can be potentially overcome 
using biomaterial vectors to deliver antigen(s) in situ. In 
recent years bio- and synthetic materials such as hydro-
gels, liposomes, matrices and nanogels which have the 
common feature of being biocompatible and non-toxic 
have been tested for the delivery of tumor antigen(s) in 
micro and nanoparticles in a great variety of combina-
tions of different building blocks, antigens, adjuvants and 
targeting molecules (Table 2) [95]. Among these, due to 
their high biocompatibility and easy approval, liposomes 
have been largely explored and have also been tested in 
the clinic. Unfortunately, while certain formulations have 
shown discrete success in Phase I [96–100] and II trials 
[101, 102] showing good tolerance and survival improve-
ment, Phase III trials have been less successful reporting 
limited benefits (BLP25 [103]) or failed to meet study 
endpoints (Allovectin-7 [104], product discontinued; 
Table  2). A major drawback of liposomes is their very 
short half life in the body and rapid clearance that lim-
its the time frame in which they are active, a feature that 
could well be at the base of their reported failures [105]. 
A possible solution to this problem could be potentially 
offered by the implementation of Poly(lactic-co-glycolic 
acid) or PLGA in nanovaccine formulations. PLGA 
offers the advantage of being itself an immunostimulat-
ing agent, contributing therefore to the overall immune 
stimulation process rather that just acting as an inert car-
rier as well as being characterized by longer persistence 
in the human body and slow cargo release [105]. Several 
types of antigens such as proteins (e.g. ovalbumin (OVA) 
[106, 107], peptides (e.g.  Hgp10025–33;  TRP2180–188) [108, 
109] and WTLs [110–113] have been encapsulated in 
PLGA nanoparticles and tested in in vitro systems and/
or in mouse models showing positive outcomes in terms 
of efficient antigen delivery and elicited tumor-specific T 
cell responses. However none of these different formula-
tions have been tested in humans yet. Another biopoly-
mer tested in the clinic for cancer vaccine delivery is 
cholesteryl pullulan. Phase I trials in esophageal [114] 
or HER2-expressing [115, 116] cancer patients were 
carried out delivering well established cancer antigens 
(NY-ESO-1 protein and HER2 fragment, respectively) 
reporting good tolerance and the occurrence of antigen 
specific immune responses, while no Phase II or III tri-
als appeared so far in the literature to our knowledge. 
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Table 2 List of recent studies investigating nanoparticle-mediated delivery of tumor antigen(s) either alone or in combi-
nation with adjuvant(s)/DC-targeting moieties for cancer therapeutic vaccination
Carrier Loaded with Study type Outcomea References
Liposome Hsp70 peptide complex Breast cancer mouse 
model
Enhanced immune response [165]
Liposome MUC1 peptide, TLR4 
ligand
Phase I–II–III studies Phase I studies: vaccine was well tolerated; phase II study in 
NSCLC: survival improvement; Phase III study in NSCLC: only 
improvement observed was in concurrent chemoradiother‑
apy with a 10.2 month improvement in median survival
[96, 97, 101, 103]
Liposome HLA‑B7 and 
β2‑microglobulin DNA
Phase II‑III studies Phase II study in metastatic melanoma had a positive outcome, 
but phase III study failed and product is currently discontin‑
ued
[102, 104]
Liposome NY‑ESO‑1, MAGE‑A3, 
tyrosinase and TPTE 
RNA
Phase I study Positive outcome in all 3 patients tested. Recruitment of more 
patients is currently undergoing
[98]
Liposome Mix of different peptides Phase I study Phase I trial positive outcome, with induced de novo and 
specific T cell response
[99, 100]
Liposome SOCS1, A20 siRNA Mouse lymphoma model Drastic enhancement in cytokine production resulting in 
significant tumor suppression
[166]
Liposome E7 HPV TC‑1 lung mouse model Induced specific  CD8+T cell response and  Treg inhibition [167]
Liposome OVA, TLR3/9 ligands C57BL/6 mouse model Increased  CD8+ T cell response [123]
γ‑PGA/Pol‑
ylysine
Empty or ovalbumin C57BL/6 mouse model Comparative study: PGA has intrinsic immunogenic properties 
and induced a stronger immune response than polylysine 
when both loaded with ovalbumin
[160]
γ‑PGA Ovalbumin C57BL/6 mouse model γ‑PGA immunogenic properties are TLR4 signalling‑dependent [168]
Cationic 
polymers 
(PE/C32)
CD40 ligand DNA, 
CpG + poly(I:C)
B16‑F10 melanoma 
mouse model
Comparative study: C32 polimer was superior to PE. TLR 
ligands had a synergistic effect in triggering immune 
response
[124]
PLGA WTL In vitro Co‑culture of patient TILs with patient DCs pulsed with 
autologous WTL‑NPs resulted in higher IFN‑γ and lower IL‑10 
production compared to soluble WTL
[110, 111]
PLGA WTL, CpG, polyI:C TRAMP mouse model Induced CTL response and tumor shrinkage [112]
PLGA WTL In vitro Increased T cell proliferation [113]
PLGA Ovalbumin TLR3/7 
ligands; CD40, CD11c, 
or DEC‑205 ab
C57BL/6 mouse model NP coating with targeting molecules (CD40, CD11c or DEC‑205 
antibodies) induced a stronger immune response
[106]
PLGA Ovalbumin, mannose C57BL/6 mouse model Decoration of ovalbumin‑NPs with mannose moieties 
increased the efficiency of ovalbumin‑specific  CD4+ and 
 CD8+ T cell responses
[107]
PLGA TRP2180–188; TLR‑4 ligand B16‑F10 melanoma 
mouse model
Immune stimulation in the tumor microenvironment, induc‑
tion of antigen‑specific  CD8+ response
[108]
PLGA Hgp10025–33  TRP2180–188 C57BL/6 mouse model Increased antigen‑specific T cell response [109]
Cholesteryl 
pullulan
HER2 fragment; NY‑
ESO‑1 protein
Phase I studies Vaccine was well tolerated and induced antigen‑specific 
immune responses
[114–116]
Chitosan Ovalbumin, alginate In vitro Sugar‑coated NP induced higher IFN‑γ production in co‑
culture assays
[169]
Chitosan WTL, mannose B16 melanoma mouse 
model
Increased tumor growth inhibition [117]
BSA/pyri‑
dine
Ovalbumin In vitro This type of nanogel had intrinsic adjuvant properties [170]
Nanogel Ovalbumin, galactose B16‑OVA mouse model (pH‑sensitive system) cytosolic antigen release; ROS produc‑
tion and increased MHC‑I antigen presentation
[133]
γ-PGA poly(γ-glutamic acid), BSA bovine serum albumin, NP nanoparticle, NSCLC non-small-cell carcinoma, PLGA poly(lactic-co-glycolic acid), TLR toll-like receptor, 
TRAMP transgenic adenocarcinoma of the mouse prostate, WTL whole tumor lysate
a Compared to free soluble agent, when applicable
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Among other materials, chitosan also showed promising 
results for future translational applications. Chitosan is a 
cationic polysaccharide able to elicit an adjuvant innate 
immune response, like PLGA, further triggering DCs 
maturation. A recent study showed for example that sub-
cutaneous injections of these NPs loaded with WTL in 
mice induced a specific cytotoxic T cell (CTL) response 
and reduced tumor size compared to control groups 
[117]. In an attempt to further improve particle uptake, 
DC-targeting and DC-maturation, several studies have 
used nano- or microparticles coated with DC-targeting 
ligands such as anti-CD40 [106, 118], anti-DEC-205 [106, 
119, 120], anti-SIGN [121, 122], carbohydrates [107, 122] 
and/or TLR agonists [112, 123, 124] (Table  2). Collec-
tively, results from all these studies confirmed the previ-
ous assumption that particle coating (or encapsulation in 
the case of TLR agonists) indeed improves DC matura-
tion, antigen internalization and presentation, inducing 
a stronger immune response compared to non-targeted 
nanovaccines or free antigen(s) in mouse model systems. 
Few comparative studies were also able to identify better 
formulations over others (e.g. uptake of SIGN-antibody 
coated-nanoparticles was more efficient that carbohy-
drates-coated ones [122]; or, in another study, coating 
with CD-40 ligand was superior to DEC-205 or CD11c in 
terms of uptake [106]), even though a systematic classifi-
cation and comparison is still lacking.
Another direction in which nanovaccine research has 
recently focused on is the development of pH-sensitive 
nanoparticles. These nanoparticles, once internalized, are 
able to disrupt endosomes leading to antigen(s) release in 
the cytosol, a process known to promote cross presenta-
tion by DCs and enhance CTL over humoral response 
[125]. This approach has been successfully attempted 
with different biomaterials including liposomes [126–
128], hydrogels [129], micelles [130, 131] and synthetic 
polymers [132]. Overall, all these studies used nano-
assisted delivery of OVA in mice as a model system and 
showed positive results including increased MHC-I anti-
gen presentation and induction of OVA-specific  CD8+ 
T cell response. Furthermore, a recent study using a pH-
sensitive galactosyl dextran-retinal (GDR) nanogel for 
OVA encapsulation was able to show that the lysosome 
rupture triggered by nanoparticles could directly induce 
reactive oxygen species (ROS) production in DCs, aug-
menting proteasome activity and downstream MHC I 
antigen presentation [133]. These interesting results sug-
gest therefore that pH-sensitive nanocarriers constitute a 
very promising scaffold for future translational work.
In conclusion, a great variety of scaffolds, materials 
and antigens have been tested for cancer vaccine deliv-
ery alone or in combination with specific surface recep-
tors, and adjuvants that can improve DC-targeting and 
maturation. Despite these efforts achieved important 
results, further comparative studies are needed in order 
to understand which are the most promising and suit-
able biomaterials and to identify the best combinations 
of antigen(s), adjuvants and targeting molecules to obtain 
the best immune response. Enhancement of cross pres-
entation by cytosol localization of the antigen(s) plays 
also a significant role in terms of  CD8+ T cell polariza-
tion and should be studied and exploited in-depth in the 
future. Finally, tests in more complex systems that better 
represent human settings (e.g. humanized mouse mod-
els) [57] and for the delivery of epitopes more clinically 
relevant (e.g. other than OVA) or more immunogenic 
(e.g. oxidized WTL [92, 93] or heated lysate [94]) will 
help in translating these strategies into the clinic as well 
as potentially achieving better therapeutic outcomes.
Circulating tumor cells isolation and detection
Circulating tumor cells (CTCs) are cancer cells that shed 
from the tumor primary site and after entering the blood-
stream extravasate and arrest at a second distal site to 
initiate cancer metastasis [134]. Despite their first report 
dates back to 1869 [135], a great amount of interest 
towards CTCs and their use as predictive biomarkers for 
cancer metastasis has only emerged in the last two dec-
ades. This is mainly due to the technical challenges linked 
with detecting and isolating very rare cells (usually one 
in  106–109 hematologic cells [136]) which are also often 
highly heterogenic [137–139]. Several bioengineering 
solutions have been recently developed addressing these 
issues. One common strategy employs magnetic nano-
particle coated with specific ligands targeting CTCs (e.g. 
anti-EpCAM) that enables CTC separation and enrich-
ment from blood samples by simply applying a mag-
netic field [136]. Other isolation techniques rely on Au 
nanoparticles, quantum dots, graphene or dendrimers 
coated with different CTC-targeting moieties such as lec-
tins, tumor antigens or aptamers and have already been 
extensively reviewed elsewhere [140–142]. Despite great 
advances in biomaterial formulations for the detection 
and isolation of CTCs, their therapeutic implications have 
been largely unexplored yet, especially in the immuno-
therapy field. CTCs can be in fact isolated with a “simple” 
blood test (often referred to as liquid biopsy), contrary to 
solid tumors which require invasive surgery, and consti-
tute a precious tool to assess genotypic and phenotypic 
features at a personalized level [143]. For example, CTCs 
genotyping and phenotyping could be potentially used 
to inform cancer vaccination strategies permitting the 
identification in real time of present antigens or, on the 
opposite, of antigen-loss due to selective pressure. On the 
other hand, isolated CTCs could constitute also a poten-
tial source of antigens to pulse autologous dendritic cells 
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for personalized cancer vaccine formulations. Analogous 
strategies have been recently applied to instruct chemo-
therapeutic regimens such as HER2-receptor antagonists 
in breast cancer patients. Surprisingly, in several cases 
HER2 was detected in CTCs in metastatic patients that 
were previously negative at original diagnosis at the pri-
mary tumor site [144–146] and in one particular study 
three over four of these patients treated with anti-HER2 
therapy (trastuzumab) showed evidence of complete or 
partial response [145]. These examples, besides demon-
strating the heterogeneity and the dynamic nature of can-
cer, illustrate also the critical role that CTCs could play in 
guiding therapeutic efforts [147]. Thus, we envisage that 
in the future new studies will appear linking CTCs analy-
sis and detection with immunotherapy. However, the suc-
cess of these future approaches will rely in the high yield 
isolation of CTCs in a viable form. To this aim, several 
proof-of-concept studies showed the possibility to isolate 
CTCs from leukapheresis products, in order to screen 
blood volumes much larger (~10 L) than the commonly 
used for CTCs analysis (5–10  mL) [148–150]. Alterna-
tively, other groups are developing implantable scaffolds 
that are able to capture and trap CTCs which could be 
subsequently recovered and analyzed [151, 152]. In 
addition to this, the material could also be seeded with 
cells, or adjuvants to modulate the immune environ-
ment within the scaffold [152]. Ongoing work is focus-
ing in further developing these proof-of-concept studies 
towards translational applications. It should also be noted 
that developments in CTCs sequestering and elimination 
will be immensely powerful in fighting cancer, consider-
ing that 90% of cancer mortality is caused by metastasis 
[153]; hence efforts in this direction could be potentially 
extremely rewarding.
Route of administration
One of the crucial aspects for a successful nanotherapy is 
the route of administration which should ensure both tar-
geted delivery of the regimen at its active site (this being 
for example the tumor site or the lymph nodes) combined 
with as few as possible collateral effects and invasiveness. 
Regarding those formulations that target the tumor site, 
several studies applied intratumoral or peritumoral injec-
tion of nanoparticles loaded with immunostimulatory 
molecules (such as: IL-12 [154], IL-15 superagonist [155], 
IL2 and TGF-β [19] among others) with positive out-
comes, reporting the initiation of an immune response in 
tumor-bearing mice. Interestingly, one particular study 
demonstrated how intratumoral injection of liposomes 
carring anti-CD137 and IL-2 enabled an otherwise lethal 
treatment (compared to soluble anti-CD137 and IL-2) 
[156]. Although intratumoral injection ensures high local 
drug concentration and targeted delivery, a lot of studies 
apply more straightforward intravenous or subcutaneous 
injections and exploit instead the above mentioned EPR 
effect to passively accumulate the cargo at the tumor site. 
However, raising evidence suggests that the EPR effect 
works in rodents but not in humans (probably due to 
the large differences in tumor-to-body weight ratio and 
differences in the tumor microenvironment, between 
murine models and human cancers) [9], a fact that 
should be taken into careful consideration for clinical 
translation. In particular, this issue could potentially be 
solved by coating the surface of nanocarriers with ligands 
targeting receptors overexpressed by cancer cells (e.g. 
transferrin, folate, epidermal growth factor or glycopro-
teins receptors [157]) allowing therefore a more focused 
and active targeting.
Regarding formulations that target instead lymph 
nodes (e.g. cancer vaccines), nanocarriers can be admin-
istered either parentally (intramuscularly or subcutane-
ously, as in the majority of the studies), or intranodally. 
In the former case, the size of the nanoparticle is crucial 
in determining the mechanism of trafficking to the lymph 
nodes. In fact, while smaller particles (<200 nm) are able 
to passively drain through lymphatic system to finally 
reach the lymph nodes, larger particles cannot and have 
to be first engulfed by peripheral DCs which then migrate 
from the injection site to the lymph nodes [74]. On the 
other hand, the intranodal injection, although more tech-
nically challenging and invasive, ensures direct delivery 
and accumulation at the lymph node enabling the use of 
also microparticles which, contrary to nanoparticles, are 
able to persist longer at the lymph node releasing their 
cargo in a more prolonged and sustained fashion [158].
Finally, in an effort to balance improved targeted deliv-
ery versus limited invasiveness, a recent study pioneered 
the use of microneedle patches (MNs) to deliver antibod-
ies against the checkpoint inhibitors PD1 and CTL4 in a 
melanoma mouse model. Results showed that MNs can 
painlessly pierce the mouse skin and efficiently deliver 
their cargo to regional lymph and capillary vessels ensur-
ing disease control in 70% of mice over 2  months (end 
time point) [159]. This promising proof-of-concept study 
shows therefore that MNs could efficiently combine tar-
get delivery with easy and non-invasive administration, 
holding great potential for delivery of also other immu-
notherapeutic regimens in the future.
Conclusion and future perspectives
As highlighted by the sheer amount of studies reviewed 
here, nanoparticle delivery systems are a very versatile 
platform to address crucial limitations of current can-
cer immunotherapy, both in  vivo and ex  vivo. In par-
ticular, nanotechnology and bioengineering approaches 
have greatly enhanced the efficacy of immunotherapies 
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by ensuring targeted delivery, limited systemic toxic-
ity, and increased local concentrations of therapeutic 
regimens. Despite many advances, a great deal of work 
is still needed in the future to further characterize and 
optimize the various platforms. First of all, comparative 
studies are importantly required to identify what are the 
most advantageous materials (e.g. liposomes versus syn-
thetic polymers etc.), sizes, compositions and other bio-
physical aspects, for each application. Few of this type of 
studies already appeared in the literature [74, 124, 160] 
but a systematic classification is still lacking. Further-
more, comparative studies aimed at identifying the best 
synergistic combinations of immunomodulatory mol-
ecules (e.g. cytokines, chemotherapeutic agents, anti-
gens etc.), coadjuvantes (e.g. TLR receptor ligands) and/
or target moieties (e.g. DC or T cell specific antibodies) 
will also help to progress the future of these therapies. 
Another key aspect to further investigate is the route of 
administration, in order to guarantee efficient delivery 
while limiting the treatment invasiveness. In this sense, 
a recent breakthrough study reported the successful use 
of MNs for the delivery of checkpoint inhibitors [159], 
a route of administration that should be further tested 
for the release of also different nanotherapies. Finally, 
apart from few cases, the majority of these formula-
tions have not been implemented yet in the clinic. To 
this aim, studies in more sophisticated models such as 
“humanized” mouse models [57, 161] that better reca-
pitulate the human settings of the disease will be key 
to support and boost future clinical translations. In 
conclusion, biomaterials constitute a powerful tool to 
overcome challenges with current immunotherapies, 
however we may have just started scratching the sur-
face of the future bioengineered solutions for cancer 
immunotherapy.
Abbreviations
ACT: adoptive T cell therapy; APC: antigen presenting cell; aAPC: artificial 
antigen presenting cell; CTC: circulating tumor cell; CTL: cytotoxic T lympho‑
cyte; DC: dendritic cell; EPR: enhanced permeability and retention effect; 
GDR: galactosyl dextran‑retinal; ICD: immunogenic cell death; TIL: infiltrated 
lymphocyte; MN: microneedle; PLGA: poly(lactic‑co‑glycolic acid); ROS: reac‑
tive oxygen species; TCR: T cell receptor; TLR: toll‑like receptor; TAA: tumor 
associated antigen; WTL: whole tumor lysate.
Authors’ contributions
CB wrote the section “Cancer vaccines”, MG wrote the rest of the paper; LK and 
H‑AK conceived, supervised, reviewed and edited the manuscript. All authors 
read and approved the final manuscript.
Author details
1 Center of Experimental Therapeutics, Department of Oncology, University 
Hospital of Lausanne, Lausanne, Switzerland. 2 Laboratoire des Polymères, 
Institut des Matériaux and Institut des Sciences et Ingénierie Chimiques, 
École Polytechnique Fédérale de Lausanne (EPFL), Bâtiment MXD, Station 
12, 1015 Lausanne, Switzerland. 3 Ludwig Cancer Research Center, University 
of Lausanne, Lausanne, Switzerland. 
Acknowledgements
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Funding
This work was supported by the ISREC Foundation, thanks to a donation from 
the Biltema Foundation.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
Received: 11 May 2017   Accepted: 13 June 2017
References
 1. McCarthy EF. The toxins of William B. Coley and the treatment of bone 
and soft‑tissue sarcomas. Lowa Orthop J. 2006;26:154–8.
 2. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Red‑
fern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellham‑
mer PF, IMPACT Study Investigators. Sipuleucel‑T immunotherapy for 
castration‑resistant prostate cancer. N Engl J Med. 2010;363:411–22.
 3. D’Errico G, Machado HL, Sainz B. A current perspective on cancer 
immune therapy: step‑by‑step approach to constructing the magic 
bullet. Clin Transl Med. 2017;6:3.
 4. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. 
Annu Rev Immunol. 2004;22:329–60.
 5. Kandalaft LE, Singh N, Liao JB, Facciabene A, Berek JS, Powell DJ, Coukos 
G. The emergence of immunomodulation: combinatorial immuno‑
chemotherapy opportunities for the next decade. Gynecol Oncol. 
2010;116:222–33.
 6. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, 
Schmitt E, Hamai A, Hervas‑Stubbs S, Obeid M, Coutant F, Métivier D, 
Pichard E, Aucouturier P, Pierron G, Garrido C, Zitvogel L, Kroemer G. 
Caspase‑dependent immunogenicity of doxorubicin‑induced tumor 
cell death. J Exp Med. 2005;202:1691–701.
 7. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle‑
based medicines: a review of FDA‑approved materials and clinical trials 
to date. Pharm Res. 2016;33:2373–87.
 8. Matsumura Y, Maeda H. A new concept for macromolecular therapeu‑
tics in cancer chemotherapy: mechanism of tumoritropic accu‑
mulation of proteins and the antitumor agent smancs. Cancer Res. 
1986;46:6387–92.
 9. Danhier F. To exploit the tumor microenvironment: since the EPR effect 
fails in the clinic, what is the future of nanomedicine? J Control Release. 
2016;244:108–21.
 10. Zhao X, Yang K, Zhao R, Ji T, Wang X, Yang X, Zhang Y, Cheng K, Liu S, 
Hao J, Ren H, Leong KW, Nie G. Inducing enhanced immunogenic cell 
death with nanocarrier‑based drug delivery systems for pancreatic 
cancer therapy. Biomaterials. 2016;102:187–97.
 11. Zhao T, Ren H, Jia L, Chen J, Xin W, Yan F, Li J, Wang X, Gao S, Qian D, 
Huang C, Hao J. Inhibition of HIF‑1α by PX‑478 enhances the anti‑
tumor effect of gemcitabine by inducing immunogenic cell death in 
pancreatic ductal adenocarcinoma. Oncotarget. 2015;6:2250–62.
 12. Kelland LR. Of mice and men: values and liabilities of the athymic 
nude mouse model in anticancer drug development. Eur J Cancer. 
2004;40:827–36.
 13. Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel). 
2011;3:3856–93.
 14. Zaharoff DA, Hoffman BS, Hooper HB, Benjamin CJ, Khurana KK, Hance 
KW, Rogers CJ, Pinto PA, Schlom J, Greiner JW. Intravesical immunother‑
apy of superficial bladder cancer with chitosan/interleukin‑12. Cancer 
Res. 2009;69:6192–9.
 15. Smith SG, Koppolu BP, Ravindranathan S, Kurtz SL, Yang L, Katz MD, 
Zaharoff DA. Intravesical chitosan/interleukin‑12 immunotherapy 
Page 12 of 16Graciotti et al. J Transl Med  (2017) 15:142 
induces tumor‑specific systemic immunity against murine bladder 
cancer. Cancer Immunol Immunother. 2015;64:689–96.
 16. Hallaj‑Nezhadi S, Lotfipour F, Dass C. Nanoparticle‑mediated interleu‑
kin‑12 cancer gene therapy. J Pharm Pharm Sci. 2010;13:472–85.
 17. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, 
Anichini A. Interleukin‑12: biological properties and clinical application. 
Clin Cancer Res. 2007;13:4677–85.
 18. Yao H, Ng SS, Huo L‑F, Chow BKC, Shen Z, Yang M, Sze J, Ko O, Li M, Yue 
A, Lu L‑W, Bian X‑W, Kung H‑F, Lin MC. effective melanoma immuno‑
therapy with interleukin‑2 delivered by a novel polymeric nanoparticle. 
Mol Cancer Ther. 2011;10:1082–92.
 19. Park J, Wrzesinski SH, Stern E, Look M, Criscione J, Ragheb R, Jay SM, 
Demento SL, Agawu A, Licona Limon P, Ferrandino AF, Gonzalez D, 
Habermann A, Flavell RA, Fahmy TM. Combination delivery of TGF‑β 
inhibitor and IL‑2 by nanoscale liposomal polymeric gels enhances 
tumour immunotherapy. Nat Mater. 2012;11:895–905.
 20. Frick SU, Domogalla MP, Baier G, Wurm FR, Mailänder V, Landfester K, 
Steinbrink K. Interleukin‑2 functionalized nanocapsules for T cell‑based 
immunotherapy. ACS Nano. 2016;10:9216–26.
 21. Hong E, Usiskin IM, Bergamaschi C, Hanlon DJ, Edelson RL, Justesen S, 
Pavlakis GN, Flavell RA, Fahmy TM. Configuration‑dependent Presenta‑
tion of Multivalent IL‑15:IL‑15Rα Enhances the Antigen‑specific T cell 
response and anti‑tumor immunity. J Biol Chem. 2016;291:8931–50.
 22. Pradhan P, Qin H, Leleux JA, Gwak D, Sakamaki I, Kwak LW, Roy K. 
The effect of combined IL10 siRNA and CpG ODN as pathogen‑
mimicking microparticles on Th1/Th2 cytokine balance in dendritic 
cells and protective immunity against B cell lymphoma. Biomaterials. 
2014;35:5491–504.
 23. Vanitha S, Chaubey N, Ghosh SS, Sanpui P. Recombinant human granu‑
locyte macrophage colony stimulating factor (hGM‑CSF): Possibility of 
nanoparticle‑mediated delivery in cancer immunotherapy. Bioengi‑
neered. 2016;8:1–4.
 24. Vanitha S, Goswami U, Chaubey N, Ghosh SS, Sanpui P. Functional char‑
acterization of recombinant human granulocyte colony stimulating 
factor (hGMCSF) immobilized onto silica nanoparticles. Biotechnol Lett. 
2016;38:243–9.
 25. Zhang Y, Cui Z, Kong H, Xia K, Pan L, Li J, Sun Y, Shi J, Wang L, Zhu Y, 
Fan C. One‑shot immunomodulatory nanodiamond agents for cancer 
immunotherapy. Adv Mater. 2016;28:2699–708.
 26. De Titta A, Ballester M, Julier Z, Nembrini C, Jeanbart L, van der Vlies AJ, 
Swartz MA, Hubbell JA. Nanoparticle conjugation of CpG enhances 
adjuvancy for cellular immunity and memory recall at low dose. Proc 
Natl Acad Sci. 2013;110:19902–7.
 27. Thomas SN, Vokali E, Lund AW, Hubbell JA, Swartz MA. Targeting the 
tumor‑draining lymph node with adjuvanted nanoparticles reshapes 
the anti‑tumor immune response. Biomaterials. 2014;35:814–24.
 28. Ramani M, Mudge MC, Morris RT, Zhang Y, Warcholek SA, Hurst 
MN, Riviere JE, DeLong RK. Zinc oxide nanoparticle‑poly I:C RNA 
complexes: Implication as therapeutics against experimen‑
tal melanoma. Mol Pharm. 2017;14:614–25. doi: 10.1021/acs.
molpharmaceut.6b00795
 29. Hafner AM, Corthésy B, Merkle HP. Particulate formulations for 
the delivery of poly(I:C) as vaccine adjuvant. Adv Drug Deliv Rev. 
2013;65:1386–99.
 30. Gammon JM, Dold NM, Jewell CM. Improving the clinical impact of 
biomaterials in cancer immunotherapy. Oncotarget. 2016;7:15421–43.
 31. Lu Y, Wang Y, Miao L, Haynes M, Xiang G, Huang L. Exploiting in situ 
antigen generation and immune modulation to enhance chemother‑
apy response in advanced melanoma: a combination nanomedicine 
approach. Cancer Lett. 2016;379:32–8.
 32. Lim YT, Heo MB, Kim S‑Y, Yun W. Sequential delivery of an anticancer 
drug and combined immunomodulatory nanoparticles for efficient 
chemoimmunotherapy. Int J Nanomed. 2015;10:5981.
 33. Roy A, Singh MS, Upadhyay P, Bhaskar S. Nanoparticle mediated co‑
delivery of paclitaxel and a TLR‑4 agonist results in tumor regression 
and enhanced immune response in the tumor microenvironment of a 
mouse model. Int J Pharm. 2013;445:171–80.
 34. Roy A, Chandra S, Mamilapally S, Upadhyay P, Bhaskar S. Anticancer and 
immunostimulatory activity by conjugate of paclitaxel and non‑toxic 
derivative of LPS for combined chemo‑immunotherapy. Pharm Res. 
2012;29:2294–309.
 35. Jehn CF, Hemmati P, Lehenbauer‑Dehm S, Kümmel S, Flath B, Schmid 
P. Biweekly pegylated liposomal doxorubicin (Caelyx) in heavily pre‑
treated metastatic breast cancer: a phase 2 study. Clin Breast Cancer. 
2016;16:514–9.
 36. Rom J, Bechstein S, Domschke C, Golatta M, Mayer C, Heil J, Thum J, 
Smetanay K, Windemuth‑Kieselbach C, Wallwiener M, Marme F, Schuetz 
F, Sohn C, Schneeweiss A. Efficacy and toxicity profile of pegylated 
liposomal doxorubicin (Caelyx) in patients with advanced breast cancer. 
Anticancer Drugs. 2014;25:219–24.
 37. Vergote I, Schilder RJ, Pippitt CH, Wong S, Gordon AN, Scudder S, 
Kridelka F, Dirix L, Leach JW, Ananda S, Nanayakkara N, Melara R, Bass 
MB, Litten J, Adewoye H, Wenham RM. A phase 1b study of trebananib 
in combination with pegylated liposomal doxorubicin or topotecan in 
women with recurrent platinum‑resistant or partially platinum‑sensitive 
ovarian cancer. Gynecol Oncol. 2014;135:25–33.
 38. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. 
Recurrent epithelial ovarian carcinoma: a randomized phase III study 
of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 
2001;19:3312–22.
 39. Swenson CE, Bolcsak LE, Batist G, Guthrie TH, Tkaczuk KH, Boxenbaum 
H, Welles L, Chow S‑C, Bhamra R, Chaikin P. Pharmacokinetics of doxoru‑
bicin administered iv as Myocet (TLC D‑99; liposome‑encapsulated 
doxorubicin citrate) compared with conventional doxorubicin when 
given in combination with cyclophosphamide in patients with meta‑
static breast cancer. Anticancer Drugs. 2003;14:239–46.
 40. Leonard RCF, Williams S, Tulpule A, Levine AM, Oliveros S. Improving the 
therapeutic index of anthracycline chemotherapy: focus on liposomal 
doxorubicin (Myocet™). Breast. 2009;18:218–24.
 41. Eitan R, Fishman A, Meirovitz M, Goldenberg H, Amit A, Koren C, 
Schneider Y, Rosengarten O, Neuman A, Keren‑Rosenberg S, Safra T. 
Liposome‑encapsulated doxorubicin citrate (Myocet) for treatment of 
recurrent epithelial ovarian cancer. Anticancer Drugs. 2014;25:101–5.
 42. Lowis S, Lewis I, Elsworth A, Weston C, Doz F, Vassal G, Bellott R, Robert 
J, Pein F, Ablett S, Pinkerton R, Frappaz D, United Kingdom Children’s 
Cancer Study Group (UKCCSG) New Agents, and Société Française 
d’Oncologie Pédiatrique (SFOP) Pharmacology Group. A phase I study of 
intravenous liposomal daunorubicin (DaunoXome) in paediatric patients 
with relapsed or resistant solid tumours. Br J Cancer. 2006;95:571–80.
 43. McTiernan A, Whelan J, Leahy M, Woll PJ, Judson I. A phase II nonran‑
domised open‑label study of liposomal daunorubicin (DaunoXome) in 
advanced soft tissue sarcoma. Sarcoma. 2006;2006:1–5.
 44. Passero FC Jr, Grapsa D, Syrigos KN, Saif MW. The safety and efficacy of 
Onivyde (irinotecan liposome injection) for the treatment of metastatic 
pancreatic cancer following gemcitabine‑based therapy. Expert Rev 
Anticancer Ther. 2016. doi:10.1080/14737140.2016.1192471.
 45. Silverman JA, Deitcher SR. Marqibo® (vincristine sulfate liposome 
injection) improves the pharmacokinetics and pharmacodynamics of 
vincristine. Cancer Chemother Pharmacol. 2013;71:555–64.
 46. Shah NN, Merchant MS, Cole DE, Jayaprakash N, Bernstein D, Delbrook 
C, Richards K, Widemann BC, Wayne AS. Vincristine sulfate liposomes 
injection (VSLI,  Marqibo®): results from a phase I study in children, ado‑
lescents, and young adults with refractory solid tumors or leukemias. 
Pediatr Blood Cancer. 2016;63:997–1005.
 47. Kaplan LD, Deitcher SR, Silverman JA, Morgan G. Phase II study of vin‑
cristine sulfate liposome injection (Marqibo) and Rituximab for patients 
with relapsed and refractory diffuse large B‑Cell lymphoma or mantle 
cell lymphoma in need of palliative therapy. Clin Lymphoma Myeloma 
Leuk. 2014;14:37–42.
 48. Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A, 
Dang NH, Forman A, McLaughlin P, Medeiros LJ, Pro B, Romaguera J, 
Samaniego F, Silverman JA, Sarris A, Cabanillas F. Long term results of 
a phase 2 study of vincristine sulfate liposome injection (Marqibo®) 
substituted for non‑liposomal vincristine in cyclophosphamide, doxo‑
rubicin, vincristine, prednisone with or without rituximab for patients 
with untreated aggressive. Br J Haematol. 2013;162:631–8.
 49. Zong Y, Wu J, Shen K. Nanoparticle albumin‑bound paclitaxel as 
neoadjuvant chemotherapy of breast cancer: a systematic review and 
meta‑analysis. Oncotarget. 2015;8:17360.
 50. Schettini F, Giuliano M, De Placido S, Arpino G. Nab‑paclitaxel for the 
treatment of triple‑negative breast cancer: rationale, clinical data and 
future perspectives. Cancer Treat Rev. 2016;50:129–41.
Page 13 of 16Graciotti et al. J Transl Med  (2017) 15:142 
 51. Leon‑Ferre RA, Markovic SN. Nab‑paclitaxel in patients with metastatic 
melanoma. Expert Rev Anticancer Ther. 2015;15:1371–7.
 52. Blair HA, Deeks ED. Albumin‑bound paclitaxel: a review in non‑small cell 
lung cancer. Drugs. 2015;75:2017–24.
 53. Alrwas A, Papadopoulos NE, Cain S, Patel SP, Kim KB, Deburr TL, Bassett 
R, Hwu W‑J, Bedikian AY, Davies MA, Woodman SE, Hwu P, Hwu P. Phase 
I trial of biochemotherapy with cisplatin, temozolomide, and dose esca‑
lation of nab‑paclitaxel combined with interleukin‑2 and interferon‑α in 
patients with metastatic melanoma. Melanoma Res. 2014;24:342–8.
 54. Adams S, Diamond J, Hamilton E, Pohlmann P, Tolaney S, Molinero L, 
He X, Waterkamp D, Funke R, Powderly J. Phase Ib trial of atezolizumab 
in combination with nab‑paclitaxel in patients with metastatic triple‑
negative breast cancer (mTNBC)., in 2016 ASCO Annual Meeting. 2016.
 55. Simpkins F, Flores A, Chu C, Berek JS, Lucci J, Murray S, Bauman J, 
Struemper H, Germaschewski F, Jonak Z, Gardner O, Toso J, Coukos G. 
Chemoimmunotherapy using pegylated liposomal doxorubicin and 
interleukin‑18 in recurrent ovarian cancer: a phase I dose‑escalation 
study. Cancer Immunol Res. 2013;1:168–78.
 56. Dijkgraaf EM, Santegoets SJAM, Reyners AKL, Goedemans R, Wouters 
MCA, Kenter GG, van Erkel AR, van Poelgeest MIE, Nijman HW, van der 
Hoeven JJM, Welters MJP, van der Burg SH, Kroep JR. A phase I trial 
combining carboplatin/doxorubicin with tocilizumab, an anti‑IL‑6R 
monoclonal antibody, and interferon‑α2b in patients with recurrent 
epithelial ovarian cancer. Ann Oncol. 2015;26:2141–9.
 57. Zhou Q, Facciponte J, Jin M, Shen Q, Lin Q. Humanized NOD‑SCID 
IL2rg–/– mice as a preclinical model for cancer research and its poten‑
tial use for individualized cancer therapies. Cancer Lett. 2014;344:13–9.
 58. Soliman H. <em>nab</em>‑Paclitaxel as a potential partner 
with checkpoint inhibitors in solid tumors. Onco Targets Ther. 
2016;10:101–12.
 59. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immu‑
notherapy for human cancer. Science (80‑.). 2015;348:62–8.
 60. Duong CPM, Yong CSM, Kershaw MH, Slaney CY, Darcy PK. Cancer 
immunotherapy utilizing gene‑modified T cells: from the bench to the 
clinic. Mol Immunol. 2015;67:46–57.
 61. Besser MJ, Shapira‑Frommer R, Itzhaki O, Treves AJ, Zippel DB, Levy D, 
Kubi A, Shoshani N, Zikich D, Ohayon Y, Ohayon D, Shalmon B, Markel 
G, Yerushalmi R, Apter S, Ben‑Nun A, Ben‑Ami E, Shimoni A, Nagler 
A, Schachter J. Adoptive transfer of tumor‑infiltrating lymphocytes 
in patients with metastatic melanoma: intent‑to‑treat analysis and 
efficacy after failure to prior immunotherapies. Clin Cancer Res. 
2013;19:4792–800.
 62. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry 
RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, 
de Vries CR, Rogers‑Freezer LJ, Mavroukakis SA, Rosenberg SA. Cancer 
regression in patients after transfer of genetically engineered lympho‑
cytes. Science (80‑.). 2006;314:126–9.
 63. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, 
Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee C‑CR, Restifo NP, 
Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, Van Waes 
C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM, Rosenberg 
SA. Gene therapy with human and mouse T‑cell receptors mediates 
cancer regression and targets normal tissues expressing cognate 
antigen. Blood. 2009;114:535–46.
 64. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler‑Stevenson 
M, Feldman SA, Maric I, Raffeld M, Raffeld M, Nathan D‑AN, Lanier BJ, 
Morgan RA, Rosenberg SA. Eradication of B‑lineage cells and regression 
of lymphoma in a patient treated with autologous T cells genetically 
engineered to recognize CD19. Blood. 2010;116:4099–102.
 65. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, 
Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes 
MS, Restifo NP, Raffeld M, Lee C‑CR, Levy CL, Li YF, El‑Gamil M, Schwarz 
SL, Laurencot C, Rosenberg SA. Tumor regression in patients with meta‑
static synovial cell sarcoma and melanoma using genetically engineered 
lymphocytes reactive with NY‑ESO‑1. J Clin Oncol. 2011;29:917–24.
 66. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, 
Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold 
SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA. 
Chimeric antigen receptor T Cells for sustained remissions in leukemia. 
N Engl J Med. 2014;371:1507–17.
 67. Stephan MT, Moon JJ, Um SH, Bershteyn A, Irvine DJ. Therapeutic cell 
engineering with surface‑conjugated synthetic nanoparticles. Nat Med. 
2010;16:1035–41.
 68. Stephan MT, Stephan SB, Bak P, Chen J, Irvine DJ. Synapse‑directed 
delivery of immunomodulators using T‑cell‑conjugated nanoparticles. 
Biomaterials. 2012;33:5776–87.
 69. Zheng Y, Stephan MT, Gai SA, Abraham W, Shearer A, Irvine DJ. In vivo 
targeting of adoptively transferred T‑cells with antibody‑ and cytokine‑
conjugated liposomes. J Control Release. 2013;172:426–35.
 70. Smith TT, Stephan SB, Moffett HF, McKnight LE, Ji W, Reiman D, Bona‑
gofski E, Wohlfahrt ME, Pillai SPS, Stephan MT. In situ programming 
of leukaemia‑specific T cells using synthetic DNA nanocarriers. Nat. 
Nanotechnol. 2017. doi:10.1038/nnano.2017.57.
 71. Smith‑Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev 
Immunol. 2009;27:591–619.
 72. Steenblock ER, Fahmy TM. A comprehensive platform for ex vivo T‑cell 
expansion based on biodegradable polymeric artificial antigen‑pre‑
senting cells. Mol Ther. 2008;16:765–72.
 73. Perica K, De León Medero A, Durai M, Chiu YL, Bieler JG, Sibener L, 
Niemöller M, Assenmacher M, Richter A, Edidin M, Oelke M, Schneck J. 
Nanoscale artificial antigen presenting cells for T cell immunotherapy. 
Nanomedicine. 2014;10:119–29.
 74. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. 
Nanoparticles target distinct dendritic cell populations according to 
their size. Eur J Immunol. 2008;38:1404–13.
 75. Perica K, Bieler JG, Schütz C, Varela JC, Douglass J, Skora A, Chiu YL, 
Oelke M, Kinzler K, Zhou S, Vogelstein B, Schneck JP. Enrichment and 
expansion with nanoscale artificial antigen presenting cells for adop‑
tive immunotherapy. ACS Nano. 2015;9:6861–71.
 76. Sunshine JC, Perica K, Schneck JP, Green JJ. Particle shape dependence 
of CD8+ T cell activation by artificial antigen presenting cells. Biomate‑
rials. 2014;35:269–77.
 77. Kumari S, Curado S, Mayya V, Dustin ML. T cell antigen receptor 
activation and actin cytoskeleton remodeling. Biochim Biophys Acta 
Biomembr. 2014;1838:546–56.
 78. Perica K, Kosmides AK, Schneck JP. Linking form to function: biophysi‑
cal aspects of artificial antigen presenting cell design. Biochim Biophys 
Acta Mol Cell Res. 2015;1853:781–90.
 79. Gottschalk RA, Hathorn MM, Beuneu H, Corse E, Dustin ML, Altan‑Bon‑
net G, Allison JP. Distinct influences of peptide‑MHC quality and quan‑
tity on in vivo T‑cell responses. Proc Natl Acad Sci USA. 2012;109:881–6.
 80. Gottschalk RA, Corse E, Allison JP. TCR ligand density and affin‑
ity determine peripheral induction of Foxp3 in vivo. J Exp Med. 
2010;207:1701–11.
 81. Shen K, Thomas VK, Dustin ML, Kam LC. Micropatterning of costimu‑
latory ligands enhances CD4+ T cell function. Proc Natl Acad Sci. 
2008;105:7791–6.
 82. Uyl‑de Groot CA, Vermorken JB, Hanna MG, Verboom P, Groot MT, 
Bonsel GJ, Meijer CJLM, Pinedo HM. Immunotherapy with autologous 
tumor cell‑BCG vaccine in patients with colon cancer: a prospective 
study of medical and economic benefits. Vaccine. 2005;23:2379–87.
 83. Hoover HC, Brandhorst JS, Peters LC, Surdyke MG, Takeshita Y, Madar‑
iaga J, Muenz LR, Hanna MG. Adjuvant active specific immunotherapy 
for human colorectal cancer: 6.5‑year median follow‑up of a phase III 
prospectively randomized trial. J Clin Oncol. 1993;11:390–9.
 84. Jonasch E, Wood C, Tamboli P, Pagliaro LC, Tu SM, Kim J, Srivastava 
P, Perez C, Isakov L, Tannir N. Vaccination of metastatic renal cell 
carcinoma patients with autologous tumour‑derived vitespen vaccine: 
clinical findings. Br J Cancer. 2008;98:1336–41.
 85. Ophir E, Bobisse S, Coukos G, Harari A, Kandalaft LE. Personalized 
approaches to active immunotherapy in cancer. Biochim Biophys Acta 
Rev Cancer. 2016;1865:72–82.
 86. Bonab F, Khansari S, Khansari N. Dendritic cell vaccine and its applica‑
tion in cancer therapy. Int J Vaccines Vaccin. 2015;1:5–9.
 87. Jäger E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A. Inverse 
relationship of melanocyte differentiation antigen expression in mela‑
noma tissues and CD8+ cytotoxic‑T‑cell responses: evidence for immu‑
noselection of antigen‑loss variants in vivo. Int J Cancer. 1996;66:470–6.
 88. Chiang CLL, Hagemann AR, Leskowitz R, Mick R, Garrabrant T, Czerniecki 
BJ, Kandalaft LE, Powell DJ, Coukos G. Day‑4 myeloid dendritic cells 
Page 14 of 16Graciotti et al. J Transl Med  (2017) 15:142 
pulsed with whole tumor lysate are highly immunogenic and elicit 
potent anti‑tumor responses. PLoS ONE. 2011;6:e28732.
 89. Mahdian R, Kokhaei P, Najar HM, Derkow K, Choudhury A, Mellstedt H. 
Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable 
of stimulating MHC‑restricted antigen‑specific antitumor T cells. Med 
Oncol. 2006;23:273–82.
 90. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with 
tumor lysate‑pulsed dendritic cells elicits antigen‑specific, cytotoxic 
T‑cells in patients with malignant glioma. Cancer Res. 2004;64:4973–9.
 91. Geiger JD, Hutchinson RJ, Hohenkirk LF, Mckenna EA, Yanik GA, Levine 
JE, Chang AE, Braun TM, Mule JJ. Vaccination of pediatric solid tumor 
patients with tumor lysate‑pulsed dendritic cells can expand specific 
T Cells and mediate tumor regression vaccination of pediatric solid 
tumor patients with tumor lysate‑pulsed dendritic cells can expand 
specific T cell. Cancer Res. 2011;61:8513–9.
 92. Kandalaft LE, Chiang CL, Tanyi J, Motz G, Balint K, Mick R, Coukos G. 
A phase I vaccine trial using dendritic cells pulsed with autologous 
oxidized lysate for recurrent ovarian cancer. J Transl Med. 2013;11:149.
 93. Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, 
Montone K, Mantia‑Smaldone GM, Nisenbaum HL, Levine BL, Kalos M, 
Czerniecki BJ, Drew A, Powell DJ Jr, Mick R, Smith L, Coukos G. A den‑
dritic cell vaccine pulsed with autologous hypochlorous acid‑oxidized 
ovarian cancer lysate primes effective broad antitumor immunity: 
from bench to bedside. Clin Cancer Res. 2013;19(17):4801–15. 
doi:10.1158/1078‑0432.CCR‑13‑1185.
 94. Kim HS, Choo YS, Koo T, Bang S, Oh TY, Wen J, Song SY. Enhancement of 
antitumor immunity of dendritic cells pulsed with heat‑treated tumor 
lysate in murine pancreatic cancer. Immunol Lett. 2006;103:142–8.
 95. Mogrão J, da Costa CA, Gaspar R, Florindo HF. Modulation of dendritic 
cells by nanotechnology‑based immunotherapeutic strategies. J 
Biomed Nanotechnol. 2016;12:405–34.
 96. North SA, Graham K, Bodnar D, Venner P. A pilot study of the liposomal 
MUC1 vaccine BLP25 in prostate specific antigen failures after radical 
prostatectomy. J Urol. 2006;176:91–5.
 97. Palmer M, Parker J, Modi S, Butts C, Smylie M, Meikle A, Kehoe M, 
MacLean G, Longenecker M. Phase I study of the BLP25 (MUC1 Peptide) 
liposomal vaccine for active specific immunotherapy in stage IIIB/IV 
non–small‑cell lung cancer. Clin Lung Cancer. 2001;3:49–57.
 98. Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, 
Fritz D, Vascotto F, Hefesha H, Grunwitz C, Vormehr M, Hüsemann Y, 
Selmi A, Kuhn AN, Buck J, Derhovanessian E, Rae R, Attig S, Diek‑
mann J, Jabulowsky RA, Heesch S, Hassel J, Langguth P, Grabbe 
S, Huber C, Türeci Ö, Sahin U. Systemic RNA delivery to dendritic 
cells exploits antiviral defence for cancer immunotherapy. Nature. 
2016;534:396–401.
 99. Berinstein NL, Karkada M, Morse MA, Nemunaitis JJ, Chatta G, Kaufman 
H, Odunsi K, Nigam R, Sammatur L, MacDonald LD, Weir GM, Stanford 
MM, Mansour M. First‑in‑man application of a novel therapeutic cancer 
vaccine formulation with the capacity to induce multi‑functional T cell 
responses in ovarian, breast and prostate cancer patients. J Transl Med. 
2012;10:156.
 100. Berinstein NL, Karkada M, Oza AM, Odunsi K, Villella JA, Nemunaitis JJ, 
Morse MA, Pejovic T, Bentley J, Buyse M, Nigam R, Weir GM, MacDonald 
LD, Quinton T, Rajagopalan R, Sharp K, Penwell A, Sammatur L, Bur‑
zykowski T, Stanford MM, Mansour M. Survivin‑targeted immunother‑
apy drives robust polyfunctional T cell generation and differentiation in 
advanced ovarian cancer patients. Oncoimmunology. 2015;4:e1026529.
 101. Sangha R, Butts C. L‑BLP25: a peptide vaccine strategy in non small cell 
lung cancer. Clin Cancer Res. 2007;13:s4652–4.
 102. Bedikian AY, Richards J, Kharkevitch D, Atkins MB, Whitman E, Gonzalez 
R. A phase 2 study of high‑dose Allovectin‑7 in patients with advanced 
metastatic melanoma. Melanoma Res. 2010;20:218–26.
 103. Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, 
Nawrocki S, Ciuleanu T‑E, Bosquée L, Trigo JM, Spira A, Tremblay L, 
Nyman J, Ramlau R, Wickart‑Johansson G, Ellis P, Gladkov O, Pereira 
JR, Eberhardt WEE, Helwig C, Schröder A, Shepherd FA. Tecemotide 
(L‑BLP25) versus placebo after chemoradiotherapy for stage III non‑
small‑cell lung cancer (START): a randomised, double‑blind, phase 3 
trial. Lancet Oncol. 2014;15:59–68.
 104. Williams R. Discontinued in 2013: oncology drugs. Expert Opin Investig 
Drugs. 2015;24:95–110.
 105. Krishnamachari Y, Geary SM, Lemke CD, Salem AK. Nanoparticle delivery 
systems in cancer vaccines. Pharm Res. 2011;28:215–36.
 106. Cruz LJ, Rosalia RA, Kleinovink JW, Rueda F, Löwik CWGM, Ossendorp 
F. Targeting nanoparticles to CD40, DEC‑205 or CD11c molecules on 
dendritic cells for efficient CD8 + T cell response: a comparative study. J 
Control Release. 2014;192:209–18.
 107. Hamdy S, Haddadi A, Shayeganpour A, Samuel J, Lavasanifar A. Activa‑
tion of antigen‑specific T cell‑responses by mannan‑decorated PLGA 
nanoparticles. Pharm Res. 2011;28:2288–301.
 108. Hamdy S, Molavi O, Ma Z, Haddadi A, Alshamsan A, Gobti Z, Elhasi 
S, Samuel J, Lavasanifar A. Co‑delivery of cancer‑associated antigen 
and Toll‑like receptor 4 ligand in PLGA nanoparticles induces 
potent CD8+ T cell‑mediated anti‑tumor immunity. Vaccine. 
2008;26:5046–57.
 109. Zhang Z, Tongchusak S, Mizukami Y, Kang YJ, Ioji T, Touma M, Reinhold 
B, Keskin DB, Reinherz EL, Sasada T. Induction of anti‑tumor cytotoxic T 
cell responses through PLGA‑nanoparticle mediated antigen delivery. 
Biomaterials. 2011;32:3666–78.
 110. Prasad S, Cody V, Saucier‑Sawyer JK, Saltzman WM, Sasaki CT, Edelson 
RL, Birchall MA, Hanlon DJ. Polymer nanoparticles containing tumor 
lysates as antigen delivery vehicles for dendritic cell‑based antitumor 
immunotherapy. Nanomedicine. 2011;7:1–10.
 111. Prasad S, Cody V, Saucier‑Sawyer JK, Fadel TR, Edelson RL, Birchall MA, 
Hanlon DJ. Optimization of stability, encapsulation, release, and cross‑
priming of tumor antigen‑containing PLGA nanoparticles. Pharm Res. 
2012;29:2565–77.
 112. Mueller M, Reichardt W, Koerner J, Groettrup M. Coencapsulation of 
tumor lysate and CpG‑ODN in PLGA‑microspheres enables success‑
ful immunotherapy of prostate carcinoma in TRAMP mice. J Control 
Release. 2012;162:159–66.
 113. Iranpour S, Nejati V, Delirezh N, Biparva P, Shirian S. Enhanced stimula‑
tion of anti‑breast cancer T cells responses by dendritic cells loaded 
with poly lactic‑co‑glycolic acid (PLGA) nanoparticle encapsulated 
tumor antigens. J Exp Clin Cancer Res. 2016;35:168.
 114. Kageyama S, Wada H, Muro K, Niwa Y, Ueda S, Miyata H, Takiguchi S, 
Sugino SH, Miyahara Y, Ikeda H, Imai N, Sato E, Yamada T, Osako M, 
Ohnishi M, Harada N, Hishida T, Doki Y, Shiku H. Dose‑dependent effects 
of NY‑ESO‑1 protein vaccine complexed with cholesteryl pullulan (CHP‑
NY‑ESO‑1) on immune responses and survival benefits of esophageal 
cancer patients. J Transl Med. 2013;11:246.
 115. Kitano S, Kageyama S, Nagata Y, Miyahara Y, Hiasa A, Naota H, Okumura 
S, Imai H, Shiraishi T, Masuya M, Nishikawa M, Sunamoto J, Akiyoshi K, 
Kanematsu T, Scott AM, Murphy R, Hoffman EW, Old LJ, Shiku H. HER2‑
specifict‑cell immune responses in patients vaccinated with truncated 
HER2 protein complexed with nanogels of cholesteryl pullulan. Clin 
Cancer Res. 2006;12:7397–405.
 116. Kageyama S, Kitano S, Hirayama M, Nagata Y, Imai H, Shiraishi T, Akiyoshi 
K, Scott AM, Murphy R, Hoffman EW, Old LJ, Katayama N, Shiku H. 
Humoral immune responses in patients vaccinated with 1–146 HER2 
protein complexed with cholesteryl pullulan nanogel. Cancer Sci. 
2008;99:601–7.
 117. Shi G‑N, Zhang C‑N, Xu R, Niu J‑F, Song H‑J, Zhang X‑Y, Wang W‑W, 
Wang Y‑M, Li C, Wei X‑Q, Kong D‑L. Enhanced antitumor immunity by 
targeting dendritic cells with tumor cell lysate‑loaded chitosan nano‑
particles vaccine. Biomaterials. 2017;113:191–202.
 118. Rosalia RA, Cruz LJ, van Duikeren S, Tromp AT, Silva AL, Jiskoot W, de 
Gruijl T, Löwik C, Oostendorp J, van der Burg SH, Ossendorp F. CD40‑
targeted dendritic cell delivery of PLGA‑nanoparticle vaccines induce 
potent anti‑tumor responses. Biomaterials. 2015;40:88–97.
 119. Saluja SS, Hanlon DJ, Sharp FA, Hong E, Khalil D, Robinson E, Tigelaar 
R, Fahmy TM, Edelson RL. Targeting human dendritic cells via DEC‑205 
using PLGA nanoparticles leads to enhanced cross‑presentation of a 
melanoma‑associated antigen. Int J Nanomed. 2014;9:5231–46.
 120. Walters AA, Somavarapu S, Riitho V, Stewart GR, Charleston B, Steinbach 
F, Graham SP. Assessment of the enhancement of PLGA nanoparticle 
uptake by dendritic cells through the addition of natural receptor 
ligands and monoclonal antibody. Vaccine. 2015;33:6588–95.
 121. Sehgal K, Ragheb R, Fahmy TM, Dhodapkar MV, Dhodapkar KM. 
Nanoparticle‑mediated combinatorial targeting of multiple human 
dendritic cell (DC) subsets leads to enhanced T cell activation via IL‑
15‑dependent DC crosstalk. J Immunol. 2014;193:2297–305.
Page 15 of 16Graciotti et al. J Transl Med  (2017) 15:142 
 122. Cruz LJ, Tacken PJ, Pots JM, Torensma R, Buschow SI, Figdor CG. Com‑
parison of antibodies and carbohydrates to target vaccines to human 
dendritic cells via DC‑SIGN. Biomaterials. 2012;33:4229–39.
 123. Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A, Bosio C, Dow S. Effi‑
cient immunization and cross‑priming by vaccine adjuvants containing 
TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol. 
2006;176:7335–45.
 124. Stone GW, Barzee S, Snarsky V, Santucci C, Tran B, Langer R, Zugates GT, 
Anderson DG, Kornbluth RS. Nanoparticle‑delivered multimeric soluble 
CD40L DNA combined with toll‑like receptor agonists as a treatment 
for melanoma. PLoS ONE. 2009;4:e7334.
 125. Joffre OP, Segura E, Savina A, Amigorena S. Cross‑presentation by 
dendritic cells. Nat Rev Immunol. 2012;12:557–69.
 126. Yuba E, Harada A, Sakanishi Y, Watarai S, Kono K. A liposome‑based anti‑
gen delivery system using pH‑sensitive fusogenic polymers for cancer 
immunotherapy. Biomaterials. 2013;34:3042–52.
 127. Yuba E, Kono Y, Harada A, Yokoyama S, Arai M, Kubo K, Kono K. The 
application of pH‑sensitive polymer‑lipids to antigen delivery for cancer 
immunotherapy. Biomaterials. 2013;34:5711–21.
 128. Yoshizaki Y, Yuba E, Sakaguchi N, Koiwai K, Harada A, Kono K. Potentia‑
tion of pH‑sensitive polymer‑modified liposomes with cationic lipid 
inclusion as antigen delivery carriers for cancer immunotherapy. Bioma‑
terials. 2014;35:8186–96.
 129. Ruff LE, Mahmoud EA, Sankaranarayanan J, Morachis JM, Katayama CD, 
Corr M, Hedrick SM, Almutairi A. Antigen‑loaded pH‑sensitive hydrogel 
microparticles are taken up by dendritic cells with no requirement for 
targeting antibodies. Integr Biol (Camb). 2013;5:195–203.
 130. Keller S, wilson JT, Patilea GI, Kern HB, Convertine AJ, Stayton PS. Neutral 
polymer micelle carriers with pH‑responsive, endosome‑releasing activ‑
ity modulate antigen trafficking to enhance CD8+ T cell responses. J 
Control Release. 2014;191:24–33.
 131. Wilson JT, Keller S, Manganiello MJ, Cheng C, Lee C‑C, Opara C, Conver‑
tine A, Stayton PS. pH‑responsive nanoparticle vaccines for dual‑deliv‑
ery of antigens and immunostimulatory oligonucleotides. ACS Nano. 
2013;7:3912–25.
 132. Wilson JT, Postma A, Keller S, Convertine AJ, Moad G, Rizzardo E, Mea‑
gher L, Chiefari J, Stayton PS. Enhancement of MHC‑I antigen presenta‑
tion via architectural control of pH‑responsive, endosomolytic polymer 
nanoparticles. AAPS J. 2015;17:358–69.
 133. Wang C, Li P, Liu L, Pan H, Li H, Cai L, Ma Y. Self‑adjuvanted nanovaccine 
for cancer immunotherapy: role of lysosomal rupture‑induced ROS in 
MHC class I antigen presentation. Biomaterials. 2016;79:88–100.
 134. Masuda T, Hayashi N, Iguchi T, Ito S, Eguchi H, Mimori K. Clinical and 
biological significance of circulating tumor cells in cancer. Mol Oncol. 
2016;10:408–17.
 135. Ashworth TR. A case of cancer in which similar cells similar to those 
in the tumour were seen in the blood after death. Aust Med J. 
1869;14:146–9.
 136. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe 
AGJ, Uhr JW, Terstappen LWMM. Tumor cells circulate in the peripheral 
blood of all major carcinomas but not in healthy subjects or patients 
with nonmalignant diseases. Clin Cancer Res. 2004;10:6897–904.
 137. Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull 
JD, Herold CI, Marcom PK, George DJ, Garcia‑Blanco MA. Circulating 
tumor cells from patients with advanced prostate and breast cancer 
display both epithelial and mesenchymal markers. Mol Cancer Res. 
2011;9:997–1007.
 138. Massard C, Oulhen M, Le Moulec S, Auger N, Foulon S, Abou‑Lovergne 
A, Billiot F, Valent A, Marty V, Loriot Y, Fizazi K, Vielh P, Farace F. Phe‑
notypic and genetic heterogeneity of tumor tissue and circulating 
tumor cells in patients with metastatic castration resistant prostate 
cancer: a report from the PETRUS prospective study. Oncotarget. 
2016;7:55069–82.
 139. McDaniel AS, Ferraldeschi R, Krupa R, Landers M, Graf R, Louw J, 
Jendrisak A, Bales N, Marrinucci D, Zafeiriou Z, Flohr P, Sideris S, Crespo 
M, Figueiredo I, Mateo J, de Bono JS, Dittamore R, Tomlins SA, Attard G. 
Phenotypic diversity of circulating tumour cells in patients with meta‑
static castration‑resistant prostate cancer. BJU Int. 2016. doi:10.1111/
bju.13631.
 140. Bhana S, Wang Y, Huang X. Nanotechnology for enrichment and detec‑
tion of circulating tumor cells. Nanomedicine. 2015;10:1973–90.
 141. Yoon HJ, Kozminsky M, Nagrath S. Emerging role of nanomaterials in cir‑
culating tumor cell isolation and analysis. ACS Nano. 2014;8:1995–2017.
 142. Myung JH, Tam KA, Park S, Cha A, Hong S. Recent advances in 
nanotechnology‑based detection and separation of circulat‑
ing tumor cells. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 
2016;8:223–39.
 143. Greene BT, Hughes AD, King MR. Circulating tumor cells: the substrate 
of personalized medicine? Front Oncol. 2012;2:69.
 144. Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, Biagioni C, Cappadona 
S, Biganzoli L, Giannini A, Di Leo A. Correlation of HER2 status between 
primary tumors and corresponding circulating tumor cells in advanced 
breast cancer patients. Breast Cancer Res Treat. 2009;118:523–30.
 145. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, 
Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, 
Vitetta E, Morrison L, Herlyn D, Terstappen LWMM, Fleming T, Fehm 
T, Tucker T, Lane N, Wang J, Uhr J. HER‑2 gene amplification can 
be acquired as breast cancer progresses. Proc Natl Acad Sci USA. 
2004;101:9393–8.
 146. Fehm T, Becker S, Duerr‑Stoerzer S, Sotlar K, Mueller V, Wallwiener D, 
Lane N, Solomayer E, Uhr J. Determination of HER2 status using both 
serum HER2 levels and circulating tumor cells in patients with recurrent 
breast cancer whose primary tumor was HER2 negative or of unknown 
HER2 status. Breast Cancer Res. 2007;9:R74.
 147. Krebs MG, Hou J‑M, Ward TH, Blackhall FH, Dive C. Circulating tumour 
cells: their utility in cancer management and predicting outcomes. Ther 
Adv Med Oncol. 2010;2:351–65.
 148. Stoecklein NH, Fischer JC, Niederacher D, Terstappen LWMM. 
Challenges for CTC‑based liquid biopsies: low CTC frequency and 
diagnostic leukapheresis as a potential solution. Expert Rev Mol Diagn. 
2016;16:147–64.
 149. Fischer JC, Niederacher D, Topp SA, Honisch E, Schumacher S, Schmitz 
N, Zacarias Fohrding L, Vay C, Hoffmann I, Kasprowicz NS, Hepp PG, 
Mohrmann S, Nitz U, Stresemann A, Krahn T, Henze T, Griebsch E, Raba 
K, Rox JM, Wenzel F, Sproll C, Janni W, Fehm T, Klein CA, Knoefel WT, 
Stoecklein NH. Diagnostic leukapheresis enables reliable detection of 
circulating tumor cells of nonmetastatic cancer patients. Proc Natl Acad 
Sci. 2013;110:16580–5.
 150. Eifler RL, Lind J, Falkenhagen D, Weber V, Fischer MB, Zeillinger R. 
Enrichment of circulating tumor cells from a large blood volume using 
leukapheresis and elutriation: proof of concept. Cytom Part B Clin 
Cytom. 2011;80B:100–11.
 151. Bersani F, Lee J, Yu M, Morris R, Desai R, Ramaswamy S, Toner M, Haber 
DA, Parekkadan B. Bioengineered implantable scaffolds as a tool to 
study stromal‑derived factors in metastatic cancer models. Cancer Res. 
2014;74:7229–38.
 152. Azarin SM, Yi J, Gower RM, Aguado BA, Sullivan ME, Goodman AG, 
Jiang EJ, Rao SS, Ren Y, Tucker SL, Backman V, Jeruss JS, Shea LD. In vivo 
capture and label‑free detection of early metastatic cells. Nat Commun. 
2015;6:8094.
 153. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev 
Cancer. 2006;6:449–58.
 154. Egilmez NK, Jong YS, Sabel MS, Jacob JS, Mathiowitz E, Bankert RB. 
In situ tumor vaccination with interleukin‑12‑encapsulated biodegrada‑
ble microspheres: induction of tumor regression and potent antitumor 
immunity. Cancer Res. 2000;60:3832–7.
 155. Hori Y, Stern PJ, Hynes RO, Irvine DJ. Engulfing tumors with synthetic 
extracellular matrices for cancer immunotherapy. Biomaterials. 
2009;30:6757–67.
 156. Kwong B, Gai SA, Elkhader J, Wittrup KD, Irvine DJ. Localized immu‑
notherapy via liposome‑anchored anti‑CD137 + IL‑2 prevents lethal 
toxicity and elicits local and systemic antitumor immunity. Cancer Res. 
2013;73:1547–58.
 157. Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: 
passive and active tumor targeting of nanocarriers for anti‑cancer drug 
delivery. J Control Release. 2010;148:135–46.
 158. Jewell CM, Bustamante Lopez SC, Irvine DJ. In situ engineering of the 
lymph node microenvironment via intranodal injection of adjuvant‑
releasing polymer particles. Proc Natl Acad Sci. 2011;108:15745–50.
 159. Wang C, Ye Y, Hochu GM, Sadeghifar H, Gu Z. Enhanced cancer 
immunotherapy by microneedle patch‑assisted delivery of anti‑PD1 
antibody. Nano Lett. 2016;16:2334–40.
Page 16 of 16Graciotti et al. J Transl Med  (2017) 15:142 
 160. Uto T, Akagi T, Akashi M, Baba M. Induction of potent adaptive immu‑
nity by the novel polyion complex nanoparticles. Clin Vaccine Immunol. 
2015;22:578–85.
 161. Holzapfel BM, Wagner F, Thibaudeau L, Levesque J‑P, Hutmacher DW. 
Concise review: humanized models of tumor immunology in the 21st 
century: convergence of cancer research and tissue engineering. Stem 
Cells. 2015;33:1696–704.
 162. Soofiyani SR, Hallaj‑Nezhadi S, Lotfipour F, Hosseini AM, Baradaran B. 
Gene therapy based on interleukin‑12 loaded chitosan nanoparticles in 
a mouse model of fibrosarcoma. Iran J. Basic Med Sci. 2016;19:1238–44.
 163. Sabel MS, Su G, Griffith KA, Chang AE. Intratumoral delivery of encap‑
sulated IL‑12, IL‑18 and TNF‑α in a model of metastatic breast cancer. 
Breast Cancer Res Treat. 2010;122:325–36.
 164. Tincer G, Yerlikaya S, Yagci FC, Kahraman T, Atanur OM, Erbatur O, Gursel 
I. Immunostimulatory activity of polysaccharide–poly(I:C) nanoparticles. 
Biomaterials. 2011;32:4275–82.
 165. Zhang Y, Luo W, Wang Y, Chen J, Liu Y, Zhang Y. Enhanced antitumor 
immunity of nanoliposome‑encapsulated heat shock protein 70 
peptide complex derived from dendritic tumor fusion cells. Oncol Rep. 
2015;33:2695–702.
 166. Warashina S, Nakamura T, Sato Y, Fujiwara Y, Hyodo M, Hatakeyama H, 
Harashima H. A lipid nanoparticle for the efficient delivery of siRNA to 
dendritic cells. J Control Release. 2016;225:183–91.
 167. Chen W, Yan W, Huang L. A simple but effective cancer vaccine consist‑
ing of an antigen and a cationic lipid. Cancer Immunol Immunother. 
2008;57:517–30.
 168. Uto T, Akagi T, Yoshinaga K, Toyama M, Akashi M, Baba M. The induction 
of innate and adaptive immunity by biodegradable poly(γ‑glutamic 
acid) nanoparticles via a TLR4 and MyD88 signaling pathway. Biomateri‑
als. 2011;32:5206–12.
 169. Thomann‑Harwood LJ, Kaeuper P, Rossi N, Milona P, Herrmann B, 
McCullough KC. Nanogel vaccines targeting dendritic cells: contribu‑
tions of the surface decoration and vaccine cargo on cell targeting and 
activation. J Control Release. 2013;166:95–105.
 170. Purwada A, Tian YF, Huang W, Rohrbach KM, Deol S, August A, Singh A. 
Self‑assembly protein nanogels for safer cancer immunotherapy. Adv 
Healthc Mater. 2016;5:1413–9.
 171. Chen DS, Mellman I. Oncology meets immunology: the cancer‑immu‑
nity cycle. Immunity. 2013;39:1–10.
